Navigation Links
Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
Date:1/14/2011

net proceeds of the offering of the Notes to fund the continued investment in and expansion of its manufacturing facilities, including the construction of a new immunotherapy manufacturing facility in Europe and the expenses associated with increasing capacity at its existing Morris Plains, New Jersey, Atlanta, Georgia and Orange County, California facilities; cover expenses in connection with pursuing non-U.S. marketing approvals for PROVENGE® (sipuleucel-T); fund new clinical trials for PROVENGE and other product candidates; finance its marketing and awareness efforts for PROVENGE; fund the ongoing hiring of additional manufacturing, sales and marketing, quality, research and development and other personnel to support PROVENGE and its other product candidates; fund additional investment in information technology infrastructure and product support systems; for third-party contract supply costs; and for general corporate purposes, including working capital.  Dendreon may also use a portion of the net proceeds to acquire strategic assets, although Dendreon currently has no agreements or commitments to do so.

In connection with the offering of the Notes, the underwriter expects to distribute in an offering registered under the Securities Act 1,787,100 outstanding shares of Common Stock (subject to minor adjustments related to the allocation of the Notes) to facilitate the hedging of the Notes by buyers of the Notes.  Dendreon has been advised by the underwriter that it purchased the shares of Common Stock from buyers of the Notes in connection with, and contingent on the closing of, the Notes offering, with a view to initially offer the shares of Common Stock to the public at a price of $35.70 per share and to subsequently offer the shares of Common Stock in one or more transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at the market prices prevailing at the time of the s
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Hutchison China MediTech Limited ... (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, ... clinical trial of HMP,s c-Met inhibitor savolitinib (AZD6094) ... cell lung cancer ("NSCLC"). AZD9291 is ... receptor (EGFR). Preliminary data on the activity of ...
(Date:5/31/2015)... June 1, 2015 Sobi, ... diseases, has selected Veeva Commercial Cloud to support ... medical. A complete solution, Veeva Commercial Cloud ... compliant content to provide a comprehensive view of ...      (Logo: http://photos.prnewswire.com/prnh/20120425/527164) , ...
(Date:5/31/2015)... , May 31, 2015 Halozyme ... company developing novel oncology and drug-delivery therapies, today ... clinical study of its investigational new drug PEGPH20 ... pancreatic cancer. The encouraging interim data ... Clinical Oncology annual meeting in an oral presentation ...
(Date:5/30/2015)... May 30, 2015 The Cholangiocarcinoma ... research for bile duct cancer, announced today the ... Fellowship Program. , The Foundation has ... throughout the country to raise awareness about cholangiocarcinoma ... support research that opens new pathways for diagnosis ...
Breaking Biology Technology:Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
... , ... marks the increasing popularity of open source software (OSS) in clinical trial electronic data ... ... OpenClinica, the rapidly growing open source clinical trial software, will gather on March 22nd, ...
... ... biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral ... conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco. ... Baltimore, MD (Vocus) ...
... ... QT Beat-to-Beat(sm) to Improve Precision and Reduce Risk of False Positives/Negatives , ... Rochester, New York (PRWEB) January ... and QT analysis, announced today that a leading global CRO has selected iCardiac as ...
Cached Biology Technology:OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 2OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 4Profectus Biosciences to Present at Key Investor Conference in January 2010 2Profectus Biosciences to Present at Key Investor Conference in January 2010 3Leading Global CRO Selects iCardiac as Preferred Vendor 2
(Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... release is available in German . 48 healthy ... at the start of the experiment, the other half a placebo. ... situations in the form of a crying child, a girl hugging ... invited to express the depth of feeling they experienced for the ...
... skin crawla bug that crawls onto your lips while you ... bites, then gorges on your blood. And if that,s not ... a potentially deadly disease. Now Jean-Paul Paluzzi, a ... believes that manipulating physiology to prevent the insects from leaving ...
... an effective way of tackling global warming despite emitting small ... Research led by the University of Edinburgh suggests that ... the Earth,s emissions of methane which is considered to be ... warming. The results contrast with a previous scientific study ...
Cached Biology News:Hormone spray improves male sensitivity 2The kiss of death: Research targets lethal disease spread by insect that bites lips 2
Tracker Datamatrix TRxD reads any 1D and 2D barcodes within 0.5 seconds....
Complete cell culture media with cytokines...
... BioChain's monkey normal multiple tissue ... specific cellular localization of genes or ... tissues. Tissues are mounted on positively ... Blots are available in the identical ...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: